A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

Status Recruiting

Clinical Trial Summary

This study includes Single agent/combination dose exploration study and the phase II study. The primary purpose of this study is to determine the maximum tolerated dose(MTD)/recommended phase II dose(RP2D) of XZP-3287 and its efficacy and safety in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04539496
Study type	Interventional
Source	Sihuan Pharmaceutical Holdings Group Ltd.
Contact	Binghe Xu, Doctor
Phone	(+86)(10)(87788826)
Email	xubinghe@csco.org.cn
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	May 22, 2018
Completion date	December 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04653740` - Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer	N/A
Completed	`NCT02091960` - A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer	Phase 2
Recruiting	`NCT05156619` - Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
Recruiting	`NCT05173103` - Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
Withdrawn	`NCT05191004` - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC	Phase 1/Phase 2
Completed	`NCT00754325` - Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor	Phase 2
Recruiting	`NCT04953377` - PFMT Educational Intervention for Patients With Advancer Breast Cancer	N/A
Completed	`NCT03240224` - Bioinformation Therapy for Breast Cancer	Phase 2/Phase 3
Recruiting	`NCT06193525` - FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test	Phase 2
Completed	`NCT03312738` - A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor	Phase 2
Active, not recruiting	`NCT05063786` - Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)	Phase 3
Recruiting	`NCT05655598` - TAS-116 Plus Palbociclib in Breast and Rb-null Cancer	Phase 1
Active, not recruiting	`NCT02499146` - Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer	Phase 1
Completed	`NCT00445458` - A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer	Phase 1/Phase 2
Recruiting	`NCT04456855` - Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Completed	`NCT04408118` - First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC	Phase 2
Recruiting	`NCT04222413` - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors	Phase 1
Completed	`NCT03205761` - Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer	Phase 2
Withdrawn	`NCT04316169` - Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer	Phase 1
Completed	`NCT00546104` - Phase II Dasatinib Study in Advanced Breast Cancer	Phase 2